{"transactions":[{"id":2774168,"issuer":{"id":8441,"kind":"organization","name":"Genprex, Inc."},"owners":[{"id":140959,"kind":"person","name":"Redman Michael Thomas","position":1,"cik":"0001703052","reported_name":"Redman Michael Thomas","relationship":{"officer":true,"officer_title":"EVP & Chief Operating Officer"}}],"security":"Stock Option (right to buy)","published_at":"2021-03-23T20:46:03.000Z","date":"2021-03-19","kind":"grant","acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"One third (1/3) of the Shares subject to the Option shall vest on each annual anniversary of March 19, 2021 so that one hundred percent (100%) of the shares subject to the Option are vested on the third anniversary of March 19, 2021, provided that the optionee continues to serve as a Service Provider (as defined in Genprex, Inc. 2018 Equity Incentive Plan) through the applicable vesting date."}],"balance_after":200000,"derivative":{"exercise_price":5.08,"exercise_date":"2024-03-19","expiration_date":"2031-03-19","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001437749-21-006912","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1595248/000143774921006912/rdgdoc.xml","form_type":"4"}},{"id":4208971,"issuer":{"id":165137,"kind":"organization","name":"Oncolix, Inc.","symbol":"oncx"},"owners":[{"id":140959,"kind":"person","name":"Redman Michael Thomas","position":1,"cik":"0001703052","reported_name":"Redman Michael Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Option to acquire Common Stock","published_at":"2017-09-14T12:58:08.000Z","date":"2017-08-03","kind":"grant","acquired":true,"shares":800000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."}],"balance_after":4800000,"derivative":{"exercise_price":0.005,"exercise_date":"2017-08-03","expiration_date":"2021-11-28","underlying":"Common Stock","underlying_shares":800000},"source":{"system":"sec-edgar","filing":"0001703052-17-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1584137/000170305217000002/primary_doc.xml","form_type":"4"}},{"id":4208970,"issuer":{"id":165137,"kind":"organization","name":"Oncolix, Inc.","symbol":"oncx"},"owners":[{"id":140959,"kind":"person","name":"Redman Michael Thomas","position":1,"cik":"0001703052","reported_name":"Redman Michael Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Option to acquire Common Stock","published_at":"2017-09-14T12:58:08.000Z","date":"2017-08-03","kind":"grant","acquired":true,"shares":2000000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."}],"balance_after":4800000,"derivative":{"exercise_price":0.015,"exercise_date":"2017-08-03","expiration_date":"2021-11-28","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001703052-17-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1584137/000170305217000002/primary_doc.xml","form_type":"4"}},{"id":4208969,"issuer":{"id":165137,"kind":"organization","name":"Oncolix, Inc.","symbol":"oncx"},"owners":[{"id":140959,"kind":"person","name":"Redman Michael Thomas","position":1,"cik":"0001703052","reported_name":"Redman Michael Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Option to acquire Common Stock","published_at":"2017-09-14T12:58:08.000Z","date":"2017-08-03","kind":"grant","acquired":true,"shares":2000000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."}],"balance_after":4800000,"derivative":{"exercise_price":0.005,"exercise_date":"2017-08-03","expiration_date":"2021-04-25","underlying":"Common Stock","underlying_shares":2000000},"source":{"system":"sec-edgar","filing":"0001703052-17-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1584137/000170305217000002/primary_doc.xml","form_type":"4"}},{"id":4208968,"issuer":{"id":165137,"kind":"organization","name":"Oncolix, Inc.","symbol":"oncx"},"owners":[{"id":140959,"kind":"person","name":"Redman Michael Thomas","position":1,"cik":"0001703052","reported_name":"Redman Michael Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Warrant to acquire Series A Preferred Stock","published_at":"2017-09-14T12:58:08.000Z","date":"2017-08-03","kind":"grant","acquired":true,"shares":14000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."}],"balance_after":28000,"derivative":{"exercise_price":0.0825,"exercise_date":"2017-08-03","expiration_date":"2020-01-16","underlying":"Series A Preferred Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001703052-17-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1584137/000170305217000002/primary_doc.xml","form_type":"4"}},{"id":4208967,"issuer":{"id":165137,"kind":"organization","name":"Oncolix, Inc.","symbol":"oncx"},"owners":[{"id":140959,"kind":"person","name":"Redman Michael Thomas","position":1,"cik":"0001703052","reported_name":"Redman Michael Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Series A Preferred Stock","published_at":"2017-09-14T12:58:08.000Z","date":"2017-08-03","kind":"grant","acquired":true,"shares":14000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Each share of Series A Preferred Stock is convertible into one share of Common Stock, subject to adjustment.  There is no expiration date for conversion."},{"field":"shares","element":"transactionShares","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."},{"field":"shares","element":"transactionShares","label":"F4","text":"Each share of Series A Preferred Stock is convertible into one share of Common Stock, subject to adjustment.  There is no expiration date for conversion."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Each share of Series A Preferred Stock is convertible into one share of Common Stock, subject to adjustment.  There is no expiration date for conversion."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares  of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options."}],"balance_after":28000,"derivative":{"exercise_price":0.075,"exercise_date":"2017-08-03","expiration_date":"2050-01-01","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001703052-17-000002","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1584137/000170305217000002/primary_doc.xml","form_type":"4"}},{"id":4208966,"issuer":{"id":165137,"kind":"organization","name":"Oncolix, Inc.","symbol":"oncx"},"owners":[{"id":140959,"kind":"person","name":"Redman Michael Thomas","position":1,"cik":"0001703052","reported_name":"Redman Michael Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2017-09-14T12:58:08.000Z","date":"2017-08-03","kind":"disposition_to_issuer","acquired":true,"shares":61465130,"ownership":{"direct":false,"nature":"see footnote"},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"As reflected on his Form 3 filed on April 11, 2017, Mr. Redman may be deemed a beneficial owner of such 61,465,130 shares owned by Oncolix, Inc., as a result of Mr. Redman being an executive officer of Oncolix, Inc., however, Mr. Redman disclaimed any such beneficial ownership in the 61,465,130 shares owned by Oncolix, Inc.  The 61,465,130 shares of common stock owned by Oncolix, Inc. were disposed to, and cancelled by, AEPP in connection with the Merger.  While Mr. Reman disclaimed any such beneficial ownership, had he owned any such beneficial interest, Mr. Redman disposed of such beneficial ownership to AEPP in connection with such cancellation as provided for in the Merger."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"As reflected on his Form 3 filed on April 11, 2017, Mr. Redman may be deemed a beneficial owner of such 61,465,130 shares owned by Oncolix, Inc., as a result of Mr. Redman being an executive officer of Oncolix, Inc., however, Mr. Redman disclaimed any such beneficial ownership in the 61,465,130 shares owned by Oncolix, Inc.  The 61,465,130 shares of common stock owned by Oncolix, Inc. were disposed to, and cancelled by, AEPP in connection with the Merger.  While Mr. Reman disclaimed any such beneficial ownership, had he owned any such beneficial interest, Mr. Redman disposed of such beneficial ownership to AEPP in connection with such cancellation as provided for in the Merger."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares  of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"As reflected on his Form 3 filed on April 11, 2017, Mr. Redman may be deemed a beneficial owner of such 61,465,130 shares owned by Oncolix, Inc., as a result of Mr. Redman being an executive officer of Oncolix, Inc., however, Mr. Redman disclaimed any such beneficial ownership in the 61,465,130 shares owned by Oncolix, Inc.  The 61,465,130 shares of common stock owned by Oncolix, Inc. were disposed to, and cancelled by, AEPP in connection with the Merger.  While Mr. Reman disclaimed any such beneficial ownership, had he owned any such beneficial interest, Mr. Redman disposed of such beneficial ownership to AEPP in connection with such cancellation as provided for in the Merger."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares  of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"As reflected on his Form 3 filed on April 11, 2017, Mr. Redman may be deemed a beneficial owner of such 61,465,130 shares owned by Oncolix, Inc., as a result of Mr. Redman being an executive officer of Oncolix, Inc., however, Mr. Redman disclaimed any such beneficial ownership in the 61,465,130 shares owned by Oncolix, Inc.  The 61,465,130 shares of common stock owned by Oncolix, Inc. were disposed to, and cancelled by, AEPP in connection with the Merger.  While Mr. Reman disclaimed any such beneficial ownership, had he owned any such beneficial interest, Mr. Redman disposed of such beneficial ownership to AEPP in connection with such cancellation as provided for in the Merger."}],"balance_after":2828000,"source":{"system":"sec-edgar","filing":"0001703052-17-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1584137/000170305217000002/primary_doc.xml","form_type":"4"}},{"id":4208965,"issuer":{"id":165137,"kind":"organization","name":"Oncolix, Inc.","symbol":"oncx"},"owners":[{"id":140959,"kind":"person","name":"Redman Michael Thomas","position":1,"cik":"0001703052","reported_name":"Redman Michael Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Series A Preferred Stock","published_at":"2017-09-14T12:58:08.000Z","date":"2017-08-03","kind":"grant","acquired":true,"shares":14000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares  of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options."}],"balance_after":28000,"source":{"system":"sec-edgar","filing":"0001703052-17-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1584137/000170305217000002/primary_doc.xml","form_type":"4"}},{"id":4208964,"issuer":{"id":165137,"kind":"organization","name":"Oncolix, Inc.","symbol":"oncx"},"owners":[{"id":140959,"kind":"person","name":"Redman Michael Thomas","position":1,"cik":"0001703052","reported_name":"Redman Michael Thomas","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"President"}}],"security":"Common Stock","published_at":"2017-09-14T12:58:08.000Z","date":"2017-08-03","kind":"grant","acquired":true,"shares":4400000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On August 3, 2017, a wholly-owned subsidiary of AEPP, AEPP Merger Sub, Inc., merged with and into Oncolix, Inc.  Oncolix was the survivor of the merger (Merger) and Oncolix became a wholly-owned subsidiary of AEPP.  In connection with the Merger, the Oncolix securities owned were converted into the right to receive securities of AEPP."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes (i) 14,000 shares of AEPP common stock issuable upon conversion of AEPP Series A Preferred stock; (ii) 14,000 shares of AEPP Series A Preferred Stock issuable upon exercise of warrants to acquire AEPP Series A Preferred Stock; (iii) 14,000 shares  of shares of AEPP common stock issuable upon the conversion of AEPP Series A Preferred Stock that may be acquired pursuant to (ii) herein; and (iv) 2,800,000 shares of AEPP Common Stock that may be acquired pursuant to options."}],"balance_after":2828000,"source":{"system":"sec-edgar","filing":"0001703052-17-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1584137/000170305217000002/primary_doc.xml","form_type":"4"}}]}